Skip to main content
SpringerLink
Log in

Die Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast

The cost of psoriasis correlates with the severity of the disease, not with the psychological burden

  • Original-Forschungsarbeit
  • Published:
PharmacoEconomics German Research Articles

Abstract

Introduction

Psoriasis is a chronic relapsing immune-mediated illness with a prevalence of 2% in Europe. Nearly 20% of the patients suffer from psoriasis at moderate to severe stage which needs a combined therapy of phototherapy and/or systemic therapy in addition to local therapeutics. Due to the incidence of severe forms, an elevated co-morbidity and the low age of manifestation the application of expensive and high-risk therapies are justified. Therefore, investigations for resource allocation to reach an optimal patient management become more and more important.

Methods

The cost of patients suffering from a moderate to severe psoriasis in Germany have been investigated by a multicentre, retrospective health services research study over a period of twelve months viewed from the society’s perspective. Cost data from 92 patients were assessed. The severity of disease has been recorded by using psychologic instruments (Dermatology Life Quality Index, DLQI; EuroQoL, EQ-5D) as well as via a physiologic scale (Psoriasis Area and Severity Index, PASI). A descriptive analysis has been performed. The coefficient of correlation has been calculated by using the Pearson correlation coefficient and the analysis of regression by using the multivariate linear regression.

Patients

Patients with moderate to severe psoriasis (PASI > 10) without joint involvement or contraindication to systemic therapy were documented.

Results

All costs were calculated using the valid prices at the time of analysis (July 2005). The therapy caused direct annual costs of €1,495 per patient; third party payers pay €1,377 of this sum and the patient’s co-payment amounts to €118. Indirect costs, amounting to €123 per patient, were caused by travel expenses and inability to work. The average from the DLQI results amounted to 11.2 from a maximum score of 30 (lowest quality of life). The average EQ-5D achieved an index value of 80.1 from a maximum score of 100 (highest possible quality of life). The average PASI delivered a result of 20.8 from 72. A correlation between severity of psoriasis and costs of disease has been found for the physiologic scale, but not for quality of life. Although the study focused on patients suffering from moderate to severe psoriasis requiring combined therapy, 18.5% were treated only locally, which shows a shortcoming of health services.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Schön MP, Boehncke WH. Psoriasis. New Engl J Med 2005; 352(18): 1899–912

    Article  PubMed  Google Scholar 

  2. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41(3): 401–7

    Article  PubMed  CAS  Google Scholar 

  3. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19(3): 225–30

    Article  PubMed  Google Scholar 

  4. Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156(2): 271–6

    Article  PubMed  CAS  Google Scholar 

  5. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13(3): 450–6

    Article  PubMed  CAS  Google Scholar 

  6. Boehncke WH, Friedrich M, Mrowietz U et al. Stellenwert von Biologics in der Psoriasis-Therapie: ein Konsensus-Papier der Arbeitsgruppe Psoriasis, Arbeitsgemeinschaft dermatologische Forschung. JDDG 2003; 1(8): 620–8

    Article  Google Scholar 

  7. Finlay AY, Coles AC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132(2): 236–44

    Article  PubMed  CAS  Google Scholar 

  8. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152(5): 861–7

    Article  PubMed  CAS  Google Scholar 

  9. Boehncke WH, Brasie RA, Barker J et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. JEADV 2006; 20(8): 988–98

    PubMed  Google Scholar 

  10. Nast A, Kopp IB, Augustin M et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. JDDG 2006; 4 (Suppl 2): S1–S126

    Article  PubMed  Google Scholar 

  11. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 (Suppl 69): 3–17

    Article  PubMed  CAS  Google Scholar 

  12. Feldmann SR, Fleischer AB jr, Reboussin DM et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37(4): 564–9

    Article  Google Scholar 

  13. Berger K, Ehlken B, Kugland B et al. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. JDDG 2005; 3(7): 511–8

    Article  PubMed  Google Scholar 

  14. Sohn S, Schöffski O, Prinz J et al. Cost of moderate to severe plaque psoriasis in Germany: A multicenter cost-of-illness-study. Dermatology 2006; 212(2): 137–44

    Article  PubMed  CAS  Google Scholar 

  15. Brook R, EuroQol Group. EuroQol: the current state of play. Health Policy 1996; 37(1): 53–72

    Article  Google Scholar 

  16. Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19(3): 210–6

    Article  PubMed  CAS  Google Scholar 

  17. Kassenärztliche Bundesvereinigung Berlin. Einheitlicher Bewertungsmaßstab (EBM) 2004. Erhältlich unter: http://www.e-bis.de/ebm/

  18. Abrechnungsstatistik der Kassenärztlichen Bundesvereinigung. Rechnerischer Punktwert arztseitige Rechnungslegung (Vertragsärztliche Versorgung, Alle Bundesländer, Alle Leistungen Jahr 2002, Ärzte in freier Praxis) für 2002; Mitteilung der Kassenärztlichen Bundesvereinigung (Dezernat 3 — Gebührenordnung und Vergütung) vom 15.03.05

  19. Gebührenordnung für Ärzte (GOÄ) 2004. Erhältlich unter: http://www.e-bis.de/goae/defaultFrame.htm

  20. Medizincontrolling/DRG Research Group. WebGrouper des Universitätsklinikums Münster 2004. Erhältlich unter: http://drg.uni-muenster.de/de/webgroup/m.webgroup.php

  21. Rote Liste. Aulendorf: Editio Cantor Verlag, 2004

  22. Gelbe Liste. Neu-Isenburg: Medizinische Medien Informations GmbH, 2004

  23. Statistisches Bundesamt Deutschland (Hrsg.). Verdiensterhebung im Produzierenden Gewerbe und im Dienstleistungsbereich für 2004. Wiesbaden: Statistisches Bundesamt, 2004

    Google Scholar 

  24. Elashoff JD. nQuery Advisor® Version 4.0 User’s Guide. Los Angeles: 2000

  25. Kirby B, Richards HL, Woo P et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45(1): 72–6

    Article  PubMed  CAS  Google Scholar 

  26. Feldman S, Behnam SM, Behnam SE et al. Involving the patient: Impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol 2005; 53(1 Suppl): S78–85

    Article  PubMed  Google Scholar 

  27. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005; 152(6): 1256–62

    Article  PubMed  CAS  Google Scholar 

  28. Smith CH, Anstey AV, Barker J et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153(3): 486–97

    Article  PubMed  CAS  Google Scholar 

  29. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal (reference N0515). Erhältlich unter: http://www.nice.org.uk/page.aspx?o=201973

Download references

Author information

Authors and Affiliations

  1. Institut für Empirische Gesundheitsökonomie, Am Ziegelfeld 28, 51399, Burscheid, Deutschland

    S. Nelles, D. Daniel, L. Stratmann,  Valeska Irrgang, T. Heinen-Kammerer & R. Rychlik

  2. Zentrum der Dermatologie und Venerologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Deutschland

    W.-H. Boehncke

Authors
  1. S. Nelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Stratmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valeska Irrgang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Heinen-Kammerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Rychlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W.-H. Boehncke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valeska Irrgang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelles, S., Daniel, D., Stratmann, L. et al. Die Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast. Pharmacoeconomics-Ger-Res-Articles 5, 3–12 (2007). https://doi.org/10.1007/BF03321569

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03321569

Search

Navigation